CORRESPONDENCE| VOLUME 22, ISSUE 5, P588-589, MAY 01, 2022 Dynamics of humoral and T-cell immunity after three BNT162b2 vaccinations in adults older than 80 years Addi J Romero-Olmedo, Axel Ronald Schulz, Svenja Hochstätter, et al Lancet Infect Dis 2022; 22: 588-589 A third mRNA-based booster vaccination is the currently favoured strategy to maintain protection against SARS-CoV-2 infection. Yet, significant waning of specific immunity within 6 m...

ORIGINAL ARTICLE Homologous and Heterologous Covid-19 Booster Vaccinations Robert L. Atmar, Kirsten E. Lyke, Meagan E. Deming, et al N Engl J Med 2022; 386:1046-1057DOI: 10.1056/NEJMoa2116414 Abstract BACKGROUND Although the three vaccines against coronavirus disease 2019 (Covid-19) that have received emergency use authorization in the United States are highly effective, breakthrough infections are occurring. Data are needed on the serial use of homologo...

ARTICLES|ONLINE FIRST A village doctor-led multifaceted intervention for blood pressure control in rural China: an open, cluster randomised trial Yingxian Sun, Jianjun Mu, Dao Wen Wang, et al. Lancet Published:April 29, 2022 DOI:https://doi.org/10.1016/S0140-6736(22)00325-7 Summary Background The prevalence of uncontrolled hypertension is high and increasing in low-income and middle-income countries. We tested the effectiveness of a multifaceted inte...

ARTICLES|ONLINE FIRST Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis Jessica Widdifield, Jeffrey C Kwong, Simon Chen, et al Lancet Rheumatol Published:April 14, 2022 DOI:https://doi.org/10.1016/S2665-9913(22)00096-0 Summary Background We estimated COVID-19 vaccine effectiveness ag...

CORRESPONDENCE Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron Gili Regev-Yochay, Tal Gonen, Mayan Gilboa, et al N Engl J Med March 16, 2022DOI: 10.1056/NEJMc2202542 TO THE EDITOR: In this open-label, nonrandomized clinical study, we assessed the immunogenicity and safety of a fourth dose of either BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) administered 4 months after the third dose in a series of three BNT162b2 doses (ClinicalTria...

ARTICLES|ONLINE FIRST Clinical features and management of human monkeypox: a retrospective observational study in the UK Hugh Adler, Susan Gould, Paul Hine, et al Lancet Infect Dis Published: May 24, 2022 DOI:https://doi.org/10.1016/S1473-3099(22)00228-6 Summary Background Cases of human monkeypox are rarely seen outside of west and central Africa. There are few data regarding viral kinetics or the duration of viral shedding and no licensed treatments...

ARTICLES| VOLUME 4, ISSUE 5, E351-E361, MAY 01, 2022 Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial MeiLan K Han, Martti Antila, Joachim H Ficker, et al Lancet Rheumatol 2022; 4: e351-e361 Summary Background COVID-19 is associated with acute respiratory distress and cytokine release syndrome. The Janus kin...

ARTICLES| VOLUME 4, ISSUE 5, E338-E350, MAY 01, 2022 Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study Luuk Wieske, Koos P J van Dam, Maurice Steenhuis, et al Lancet Rheumatol 2022; 4: e338-e350 Summary Background Disease-specific studies have reported impaired humoral responses after SARS-CoV-2 vaccination in patients with immune-me...

Original Investigation March 14, 2022 Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial Anil Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez, et al JAMA. Published online March 14, 2022. doi:10.1001/jama.2022.2832 Key Points Question  Among patients at risk of disease progression, does early treatment of mild to moderate COVID-19 with the neutralizing an...

Research Letter May 19, 2022 Severity and Incidence of Multisystem Inflammatory Syndrome in Children During 3 SARS-CoV-2 Pandemic Waves in Israel Nitai Levy, Jordanna H. Koppel, Or Kaplan, et al JAMA. Published online May 19, 2022. doi:10.1001/jama.2022.8025 Multisystem inflammatory syndrome in children (MIS-C) is a serious complication of SARS-CoV-2 infection.1 A previous study that described MIS-C cases in the first 3 waves of the COVID-19 pan...